Base Pair Biotechnologies

Aptamers selected to differentiate between nerve agents VX and Sarin, selected in vitro without use of living cells or animals.

Aptamers selected by Base Pair for binding to Zika virus in mosquito saliva, useful for environmental and industrial testing.

Aptamers selected for binding to pork tapeworm in fecal homogenate, demonstrating aptamer binding in complex biological samples.

Aptamers selected by Base Pair that enter specific cells, evaluated for targeted drug delivery and in vivo diagnostics and therapeutics.

Aptamer targeting CD19 protein in humans.

Aptamer targeting CD20 protein in humans.

Aptamer targeting CD63 protein in humans.

Aptamer targeting CD45 protein in humans.

A biosensor using IL-6 aptamers conjugated to PASE and adsorbed on single wall carbon nanotubes for rapid, sensitive detection of murine IL-6 protein biomarker.

Aptamer to Human Interleukin-6 (IL-6) Cytokine selected by Base Pair Biotechnologies using proprietary methods for binding to recombinant Human Interleukin-6.

A collagen aptamer selected by Base Pair Biotechnologies scientists using proprietary methods and human placental collagen protein as a target.

A competitive aptamer-based lateral flow assay (LFA) developed for selective detection of zearalenone (ZEN), a mycotoxin found in moldy cereals and dairy products, using an anti-ZEN aptamer conjugated to gold nanoparticles.

A lateral flow assay utilizing aptamer binding to gold nanoparticles for detection of cortisol in sweat with a lower limit of detection of 1 ng/mL.

Electrochemical sensor using aptamers for real-time measurement of small molecule drugs like cocaine, doxorubicin, kanamycin, and tobramycin in whole blood, enabling pharmacokinetic and dosing studies.

DNA aptamer selected against the Zika envelope protein in mosquito saliva, also binding the Zika envelope protein in serum and defibrinated blood.

An aptamer selective for lung adenocarcinoma cells and elastic fibers of transformed tumor arteries, used for staining postoperative lung adenocarcinoma tissue.

An aptamer selective for connective tissue and blood vessels positive for lung adenocarcinoma, used for staining postoperative lung adenocarcinoma tissue.

An aptamer that binds both positive cells and connective tissues in lung adenocarcinoma, used for staining postoperative lung adenocarcinoma tissue.

DNA aptamer targeting mouse Matrix metalloproteinase-3 (MMP-3), an enzyme linked to metastatic osteosarcoma.

Natural DNA aptamer selected by Base Pair for the antibiotic tetracycline, used for detection and monitoring applications.

Patented, multiplexed, simultaneous aptamer selection against related targets coupled with deep, next-generation sequencing allowing identification of aptamers with unique binding properties via comparative analysis.

Patented multiplex aptamer selection enabling discovery of aptamers to multiple targets in a single project, decreasing time and cost for aptamer discovery.

A proprietary bioinformatics service that evaluates up to 10 million sequences from next generation sequencing to identify the best aptamer candidates based on sequence length, frequency count, predicted stability, and sequence motifs.

Aptamer M3 is a DNA aptamer selected for high affinity and selectivity to highly metastatic breast cancer cell lines, used for enrichment and detection of circulating tumor cells (CTCs).

Conformationally correct non-natural DNA aptamers available for over 400 GPCR targets, suitable for functional assays, screening, and more.

Aptamers to a wide range of targets available for research purposes through an online ordering system.

An aptamer selected to target MRSA PBP-2a bacterial protein, conferring resistance to B lactam antibiotics in MRSA infections. Selected using proprietary methods and recombinant Staphylococcus aureus PBP2a as a target.

COVID-19 aptamers are available for purchase from Base Pair Biotechnologies.

Aptamer Ap7 is a DNA aptamer selected for high affinity and selectivity to early stage gastric cancer cells, used for biomarker discovery and diagnostic applications.

Aptamer targeting Dengue Type 2 NS1 viral protein.

Aptamer targeting Botulinum Neurotoxin type B.

Aptamers developed to several canine oncology biomarkers using Base Pair's patented multiplex detection technology for rapid discovery of new affinity reagents.

Aptamer targeting CEACAM1 (CD66a) protein in humans.

Aptamer targeting Cytokeratin 19 protein.

An aptamer that binds the beta subunit of F1F0 ATP synthase (ATP5B) with high selectivity for metastatic breast and prostate cancer tissue, used for plasma membrane staining correlating with tumor stage and metastasis.

An aptamer used to detect norepinephrine and epinephrine, hormones and neurotransmitters involved in blood pressure regulation and energy production. Successfully used in plasmonic assays for serotonin detection.

Aptamer targeting Cancer Antigen 125 in humans.

Aptamer targeting Cytomegalovirus pp65 protein.

Aptamer targeting Chloride Intracellular Channel 1 (CLIC1) protein in humans.

Aptamer selected from a randomized 40-mer library against Hemoglobin protein, validated by Bio-Layer Interference (BLI) method with an average Kd of 7.7 nM. It includes 40 DNA nucleotides (45 with 3'-5T) and a molecular weight of 14,256.4 g/mol.

Aptamer for detection of the anti-retroviral drug tenofovir, used in field-effect biosensors with clinical sensitivity for HIV and Hepatitis B treatment monitoring.

Aptamers selected to bind THC in human saliva but not its long half-life metabolite, using negative selection to improve specificity.

Aptamer targeting AMACR protein in humans.

Aptamer targeting Brain Natriuretic Peptide BNP-32 in humans.

An aptamer selective for Annexin A2 protein that blocks adhesion and proliferation of multiple myeloma cells, suggesting potential therapeutic use for multiple myeloma treatment.

An aptamer selected to GPC3, a cell surface protein highly expressed in hepatocellular carcinoma (HCC) tissue, labeled with Alexa Fluor™ 750 for near-infrared imaging of HCC tumors in vivo and ex vivo.

An RNA aptamer that binds amyloid plaques both ex vivo and in vivo, used for detection of amyloid plaques in Alzheimer's disease tissue samples and transgenic mice models.

Aptamer targeting Chorionic Gonadotropin (hCG) protein in humans.

Aptamer targeting alpha B Crystallin protein in humans.

A selective aptamer targeting α-synuclein protein aggregation, inhibiting aggregation and promoting intracellular degradation, with potential to prevent and reduce toxic effects in Parkinson's disease.

Aptamer developed for detection and monitoring of the amino acid citrulline, a biomarker for renal and intestinal failure and neuropsychiatric symptoms.

Aptamers showing affinity for both the PBP-2a recombinant protein and MRSA bacteria, used for rapid detection of bacterial infections including MRSA.

Aptamer BC007 is developed as a broad spectrum neutralizer targeting the GPCR-AAB FAB fragment, showing potential utility as an in vivo treatment for dementia patients by neutralizing functional autoantibodies.

Aptamer for detection and monitoring of the small molecule drug epirubicin, useful for therapeutic drug monitoring.

Aptamer targeting CD8 protein in murine models.

A DNA aptamer that blocks Toll-like receptor 4 (TLR4) activity, showing protective effects against acute stroke in animal models by reducing ischemic brain injury and demonstrating presence in blood and brain.

Base Pair Biotechnologies uses proprietary aptamers in a novel electrochemical sensor designed for rapid testing of saliva samples for Covid-19 detection.

A DNA aptamer designed for fibronectin, studied for stability in human serum at 37°C over up to 14 days with various modifications to extend half-life.

Aptamers with high selectivity and affinity to several opioids and opioid metabolites for detection in neonatal urine, including oxycodone, hydrocodone, fentanyl, and their primary metabolites.

Nanowire-Aptamer probes created by Base Pair Biotechnologies in collaboration with Vista Therapeutics, using Vista's proprietary 'Universal Linker' system to attach aptamers to nanowires for sensitive biomarker measurement in human serum.

Aptamer against hypoxia-inducible factor-1α (HIF-1α) conjugated to PEG- and Mn(II)-modified magnetic nanoparticles for enhanced MRI imaging of hypoxia-induced cancer stem cells.

Services to modify aptamers by nucleotide substitution, functional group addition, and dye/label addition to enhance performance such as affinity, stability, and detection capability.

Custom cell culture services tailored for academic research, biotechnology, and pharmaceutical industries, including mammalian and bacterial cell culture for protein expression, assay development, drug screening, and functional studies.

Characterization services including affinity analysis using microscale thermophoresis (MST) and functional testing for ELASA, pull-down assays, LFAs, and other applications.

Service to submit enriched aptamer pools for next generation sequencing and request sequences or perform bioinformatics analysis.

A series of webinars presented by Bill Jackson Ph.D. covering aptamer advantages in drug development, aptamer applications, and aptamer-based biosensors.

Affinity testing service using Bio-Layer Interferometry (BLI) to determine aptamer-target binding characteristics, including association rate, dissociation rate, and affinity constant (KD).

High-resolution ITC services to measure thermodynamic properties of biomolecular interactions including binding affinity, enthalpy, entropy, and stoichiometry for drug discovery, biomolecular engineering, and aptamer selection.

A cloud-based collaborative tool by Base Pair Biotechnologies to keep project members up-to-date and manage affinity reagent development projects in one central place.

Ready-to-use buffer designed for thiolated aptamers to simplify handling and improve performance, offered free with any catalog aptamer order through March 2018.